TGFβ drives immune evasion in genetically reconstituted colon cancer metastasis
The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Abstract
Most patients with colorectal cancer die as a result of the disease spreading to other organs. However, no prevalent mutations have been associated with metastatic colorectal cancers. Instead, particular features of the tumour microenvironment, such as lack of T-cell infiltration, low type 1 T-helper cell (T H 1) activity and reduced immune cytotoxicity or increased TGFβ levels predict adverse outcomes in patients with colorectal cancer. Here we analyse the interplay between genetic alterations and the tumour microenvironment by crossing mice bearing conditional alleles of four main colorectal cancer mutations in intestinal stem cells. Quadruple-mutant mice developed metastatic intestinal tumours that display key hallmarks of human microsatellite-stable colorectal cancers, including low mutational burden, T-cell exclusion and TGFβ-activated stroma. Inhibition of the PD-1-PD-L1 immune checkpoint provoked a limited response in this model system. By contrast, inhibition of TGFβ unleashed a potent and enduring cytotoxic T-cell response against tumour cells that prevented metastasis. In mice with progressive liver metastatic disease, blockade of TGFβ signalling rendered tumours susceptible to anti-PD-1-PD-L1 therapy. Our data show that increased TGFβ in the tumour microenvironment represents a primary mechanism of immune evasion that promotes T-cell exclusion and blocks acquisition of the T H 1-effector phenotype. Immunotherapies directed against TGFβ signalling may therefore have broad applications in treating patients with advanced colorectal cancer.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Blockade of the TGFβ signaling pathway promotes enough T cell infiltration to make tumors sensitive to PD-1 therapy [39].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [39]
In the citing paper
“Cell analysis of human and mouse CRC specimens showed that CAF is a major contributor to TGF-β production [39].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [39]
In the citing paper
“It has been demonstrated in a variety of tumor models, including CRC models, that activation of CAF may induce PD-1 and CTLA-4 expression on relevant immune cells, which leads to tumor insensitivity to immunotherapy or recurrence [39,304,305,306].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [39]
In the citing paper
“A landmark study from 2018 demonstrated that TGF-β contributes to immune exclusion in colorectal liver metastasis and that inhibition of the TGF-β receptor 1 using the drug galunisertib enhanced tumorous infiltration with T cells, inhibited outgrowth of liver metastases and synergised with anti-PD-L1 therapy to eradicate established lesions.161”
From Current and emerging concepts for systemic treatment of metastatic colorectal cancer (2025) · cites this paper as [161]
In the citing paper
“leading to the proposition that combined TGFβ targeting and immune checkpoint blockade may represent an attractive therapeutic strategy for CMS4 colorectal cancer (34).”
From Clinical Challenges of Consensus Molecular Subtype CMS4 Colon Cancer in the Era of Precision Medicine (2024) · cites this paper as [34]
17 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing
Benjamini, Y., & Hochberg, Y. (1995) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1995.tb02031.x · Cited by 109,482
Fitting Linear Mixed-Effects Models Using lme4
Bates, D., Mächler, M., Bolker, B., & Walker, S. (2015) · Journal of Statistical Software · doi:10.18637/jss.v067.i01 · Cited by 86,835
lmerTest Package: Tests in Linear Mixed Effects Models
Kuznetsova, A., Brockhoff, P. B., & Christensen, R. H. B. (2017) · Journal of Statistical Software · doi:10.18637/jss.v082.i13 · Cited by 24,346
ggplot2: Elegant Graphics for Data Analysis
Wickham, H. (2009) · doi:10.1007/978-0-387-98141-3 · Cited by 14,447
Data Analysis Using Regression and Multilevel/Hierarchical Models
Gelman, A., & Hill, J. (2006) · doi:10.1017/cbo9780511790942 · Cited by 13,597
A genetic model for colorectal tumorigenesis
Fearon, E. R., & Vogelstein, B. (1990) · Cell · doi:10.1016/0092-8674(90)90186-i · Cited by 12,132
Signatures of mutational processes in human cancer
Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Comprehensive molecular characterization of human colon and rectal cancer
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11252 · Cited by 8,499
Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome
Galon, J., Costes, A., Sanchez-Cabo, F., Kirilovsky, A., Mlecnik, B., Lagorce-Pagès, C., Tosolini, M., Camus, M., Berger, A., Wind, P., et al. (2006) · Science · doi:10.1126/science.1129139 · Cited by 6,516
Cited by
Items 501–600 of 1,002
Targeting HIC1/TGF-β axis-shaped prostate cancer microenvironment restrains its progression
Wu, T., Wang, W., Shi, G., Hao, M., Wang, Y., Yao, M., Huang, Y., Du, L., Zhang, X., Ye, D., et al. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-05086-z · Cited by 63
CAF-immune cell crosstalk and its impact in immunotherapy
Maia, A. R. R., Schöllhorn, A., Schuhmacher, J., & Gouttefangeas, C. (2022) · Seminars in Immunopathology · doi:10.1007/s00281-022-00977-x · Cited by 63
“Several others have shown similar results and implicated TGFβ signatures in resistance to ICIs in a multiplicity of cancer entities [69, 91], as well as improved T cell penetration in the tumour upon TGFβ inhibition [40, 91, 92].”
ResultOwen, J. S., Clayton, A., & Pearson, H. B. (2022) · Biomolecules · doi:10.3390/biom13010067 · Cited by 66
Wei, F., Azuma, K., Nakahara, Y., Saito, H., Matsuo, N., Tagami, T., Kouro, T., Igarashi, Y., Tokito, T., Kato, T., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-006788 · Cited by 67
The fibroinflammatory response in cancer
Xiao, Z., & Puré, E. (2025) · Nature reviews. Cancer · doi:10.1038/s41568-025-00798-8 · Cited by 74
Lymph-node-derived stem-like but not tumor-tissue-resident CD8+ T cells fuel anticancer immunity
Wijesinghe, S. K. M., Rausch, L., Gabriel, S. S., Galletti, G., Luca, M. D., Qin, L., Wen, L., Tsui, C., Man, K., Heyden, L., et al. (2025) · Nature Immunology · doi:10.1038/s41590-025-02219-2 · Cited by 73
“Prior studies have attributed its effects to CD4 + T cells 59 , CD8 + T cells 60 , and the tumor bed 57,58 .”
Urosevic, J., Blasco, M. T., Lope, A. L., Bellmunt, A., Berenguer, A., Guiu, M., Cañellas-Socias, A., Fernández, E., Burkov, I., Clapés, M., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-19-4028 · Cited by 62
Self-citationDai, L., Li, X., Zheng, X., Fu, Z., Yao, M., Meng, S., Zhang, J., Han, B., Gao, Q., Chang, J., et al. (2021) · Biomaterials · doi:10.1016/j.biomaterials.2021.121010 · Cited by 59
Targeting of the Cancer-Associated Fibroblast—T-Cell Axis in Solid Malignancies
Harryvan, T. J., Verdegaal, E. M. E., Hardwick, J. C. H., Hawinkels, L. J. A. C., & van der Burg, S. H. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8111989 · Cited by 57
“However, recently, two independent studies have shown the role of TGF-β signaling in CAFs on T-cell infiltration and the subsequent response to checkpoint inhibition [69,70].”
BackgroundResultDecoding the interplay between genetic and non-genetic drivers of metastasis
Karras, P., Black, J. R., McGranahan, N., & Marine, J. (2024) · Nature · doi:10.1038/s41586-024-07302-6 · Cited by 68
“Tumour cells can also co-opt an immuno suppressive microenvironment: in colorectal tumours, elevated expression of TGF-β in the TME leads to immune evasion, promoting T cell exclusion and, eventually, metastasis 145 .”
BHLHA15-Positive Secretory Precursor Cells Can Give Rise to Tumors in Intestine and Colon in Mice
Hayakawa, Y., Tsuboi, M., Asfaha, S., Kinoshita, H., Niikura, R., Konishi, M., Hata, M., Oya, Y., Kim, W., Middelhoff, M. A., et al. (2018) · Gastroenterology · doi:10.1053/j.gastro.2018.11.024 · Cited by 54
Ubiquitin Ligases in Cancer Immunotherapy – Balancing Antitumor and Autoimmunity
Fujita, Y., Tinoco, R., Li, Y., Senft, D., & Ronai, Z. A. (2019) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2019.02.002 · Cited by 58
Explaining the unexplainable: discrepancies in results from the CALGB/SWOG 80405 and FIRE-3 studies
Aderka, D., Stintzing, S., & Heinemann, V. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30172-x · Cited by 54
The Tumor Microenvironment of Colorectal Cancer Metastases: Opportunities in Cancer Immunotherapy
Kamal, Y., Schmit, S. L., Frost, H. R., & Amos, C. I. (2020) · Immunotherapy · doi:10.2217/imt-2020-0026 · Cited by 60
Malacrida, B., Nichols, S. J., Maniati, E., Jones, R. R., Delanie-Smith, R., Roozitalab, R., Tyler, E. J., Thomas, M., Boot, G. F., Mackerodt, J., et al. (2021) · iScience · doi:10.1016/j.isci.2021.102676 · Cited by 57
Immunotherapy in soft tissue and bone sarcoma: unraveling the barriers to effectiveness
Panagi, M., Pilavaki, P., Constantinidou, A., & Stylianopoulos, T. (2022) · Theranostics · doi:10.7150/thno.72800 · Cited by 61
“Inhibition of TGFβ in mouse tumor models has been shown to trigger potent T cell responses [191], upregulate the expression VCAM-1 and ICAM-1 adhesion molecules [193] and promote the abscopal effect of radiotherapy [194].”
BackgroundDiazzi, S., Tartare‐Deckert, S., & Deckert, M. (2023) · Oncogenesis · doi:10.1038/s41389-023-00452-8 · Cited by 72
Stemness in solid malignancies: coping with immune attack
Agudo, J., & Miao, Y. (2024) · Nature reviews. Cancer · doi:10.1038/s41568-024-00760-0 · Cited by 72
“One promising strategy is to combine ICB with TGFβ blockade, as TGFβ signalling has a crucial role in enhancing immune resistance of colon and bladder cancer CSCs 114,115 .”
Rea, A., Santana-Hernández, S., Villanueva, J., Sanvicente-García, M., Cabo, M., Suárez-Olmos, J., Quimis, F. G., Qin, M., Llorens, E., Blasco-Benito, S., et al. (2025) · Nature Immunology · doi:10.1038/s41590-025-02103-z · Cited by 66
“Most solid tumors are poorly permeable to NK cells, partially due to the influence of TGFβ, a suppressive cytokine produced by tumor cells and other regulatory cells in the TME 6,7 .”
InfluentialLi, M., Li, G., Kiyokawa, J., Tirmizi, Z. A., Richardson, L. G., Ning, J., Das, S., Martuza, R. L., Stemmer-Rachamimov, A. O., Rabkin, S. D., et al. (2020) · Acta Neuropathologica Communications · doi:10.1186/s40478-020-01096-0 · Cited by 61
Baseline T cell dysfunction by single cell network profiling in metastatic breast cancer patients
Formenti, S. C., Hawtin, R. E., Dixit, N., Evensen, E., Lee, P., Goldberg, J. D., Li, X., Vanpouille-Box, C., Schaue, D., McBride, W. H., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0633-x · Cited by 53
Ren, Q., Zhu, P., Zhang, H., Ye, T., Liu, D., Gong, Z., & Xia, X. (2020) · Cancer Cell International · doi:10.1186/s12935-020-01173-3 · Cited by 61
Fujishita, T., Kojima, Y., Kajino‐Sakamoto, R., Mishiro‐Sato, E., Shimizu, Y., Hosoda, W., Yamaguchi, R., Taketo, M. M., & Aoki, M. (2022) · Cancer Research · doi:10.1158/0008-5472.can-22-1369 · Cited by 58
Akkız, H. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24043941 · Cited by 60
“It has been observed that CAFs lose their fibroblastic properties and become deactivated during chronic hypoxia, indicating that CAFs may transdifferentiate into a quiescent phenotype [95,96].”
BackgroundClinical immunotherapy in pancreatic cancer
Ye, X., Yu, Y., Zheng, X., & Ma, H. (2024) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-024-03632-6 · Cited by 62
Tan, H., Cao, Z., He, T., Huang, T., Xiang, C., & Liu, Y. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s178618 · Cited by 52
O’Meara, T. A., Marczyk, M., Qing, T., Yaghoobi, V., Blenman, K., Cole, K. S., Pelekanou, V., Rimm, D. L., & Pusztai, L. (2020) · JCO Precision Oncology · doi:10.1200/po.19.00350 · Cited by 59
“Overall, high TGF-β signaling is also associated with lesser response to immune checkpoint inhibitors.(41,42) On an expression level, we found higher relative fractions of CD8 T cells in immune-rich ER-positive BCs as well as higher TGF-β signaling; these CD8 T cells in immune-rich ER-positive patients may therefore l…”
BackgroundActin Cytoskeleton and Regulation of TGFβ Signaling: Exploring Their Links
Melchionna, R., Trono, P., Tocci, A., & Nisticò, P. (2021) · Biomolecules · doi:10.3390/biom11020336 · Cited by 63
Unraveling resistance to immunotherapy in MSI-high colorectal cancer
Heregger, R., Huemer, F., Steiner, M., Gonzalez-Martinez, A., Greil, R., & Weiss, L. (2023) · Cancers · doi:10.3390/cancers15205090 · Cited by 52
“TGF-β may also induce resistance to ICI treatment in dMMR/MSI-H CRC, primarily due to TGF-β -mediated T-cell inhibition [74,76–78].”
BackgroundInfluentialDanielpour, D. (2024) · Pharmaceuticals · doi:10.3390/ph17040533 · Cited by 65
Soundararajan, R., Maurin, M. M., Rodriguez-Silva, J. A., Upadhyay, G., Alden, A. J., Gowda, S. G. B., Schell, M. J., Yang, M., Levine, N. J., Gowda, D., et al. (2024) · Gut · doi:10.1136/gutjnl-2024-332535 · Cited by 63
Underlying mechanisms and drug intervention strategies for the tumour microenvironment
Li, H., Zhou, L., Zhou, J., Li, Q., & Ji, Q. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-01893-y · Cited by 56
“Embeline Growth of pancreatic cancer Increasing the infiltration of Th1 cells, NK, CTL, γ δ T and NKT, and reducing the infiltration of Th17, PMN-MDSC, IL-8 and IL-6 positive immune cells In vitro and in vivo test [103]”
BackgroundHe, F., Chen, Z., Deng, W., Zhan, T., Huang, X., Zheng, Y., & Yang, H. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.107789 · Cited by 54
Targeting cancer-associated fibroblasts: Challenges, opportunities and future directions
Jenkins, B. H., Buckingham, J. F., Hanley, C. J., & Thomas, G. J. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108231 · Cited by 57
Kurago, Z., Guo, G. F., Shi, H., Bollag, R. J., Groves, M., Byrd, J. K., & Cui, Y. R. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1212209 · Cited by 53
Blockade of TGF-β signaling: a potential target for cancer immunotherapy?
Ungefroren, H. (2019) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2019.1636034 · Cited by 50
Serrated Colorectal Cancer: The Road Less Travelled?
Nakanishi, Y., Díaz-Meco, M. T., & Moscat, J. (2019) · Trends in cancer · doi:10.1016/j.trecan.2019.09.004 · Cited by 60
TGF‐β signaling in liver metastasis
Marvin, D. L., Heijboer, R., ten Dijke, P., & Ritsma, L. (2020) · Clinical and Translational Medicine · doi:10.1002/ctm2.160 · Cited by 57
Qin, W., Zou, J., Huang, Y., Liu, C., Kang, Y., Han, H., Tang, Y., Li, L., Liu, B., Zhao, W., et al. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1824631 · Cited by 63
Zhang, N., Zhang, H., Wang, Z., Dai, Z., Zhang, X., Cheng, Q., & Liu, Z. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.691811 · Cited by 63
“Additionally, high TME-score had the distinct biological characteristics regarding stroma signatures such as TGF-beta response and leukocyte fraction compared with low TME-score, and these stroma signatures have previously been proved to facilitate the immune escape of cancer (46).”
BackgroundLoh, J. J., & Ma, S. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.727640 · Cited by 53
Mechanisms of colorectal liver metastasis development
Shasha, T., Gruijs, M., & van Egmond, M. (2022) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-022-04630-6 · Cited by 57
“In addition, it was demonstrated that murine CRC models with elevated levels of TGF-β-activated stroma display T cell exclusion, which cannot be reversed with anti-PD-1/ PD-L1 immunotherapy [152].”
BackgroundYang, Y., Xu, W., Peng, D., Wang, H., Zhang, X., Wang, H., Xiao, F., Zhu, Y., Ji, Y., Gulukota, K., et al. (2019) · Human Gene Therapy · doi:10.1089/hum.2019.059 · Cited by 54
Molecular subtypes and the evolution of treatment management in metastatic colorectal cancer
Martini, G., Dienstmann, R., Ros, J., Baraibar, I., Cuadra‐Urteaga, J. L., Salvà, F., Ciardiello, D., Mulet-Margalef, N., Argilés, G., Tabernero, J. M., et al. (2020) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835920936089 · Cited by 63
Tumor Cell–Derived TGFβ1 Attenuates Antitumor Immune Activity of T Cells via Regulation of PD-1 mRNA
Wu, P., Geng, B., Chen, Q., Zhao, E., Liu, J., Sun, C., Zha, C., Shao, Y., You, B., Zhang, W., et al. (2020) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-20-0113 · Cited by 54
Autoimmunity linked protein phosphatase PTPN22 as a target for cancer immunotherapy
Cubas, R. A., Khan, Z., Gong, Q., Москаленко, М., Xiong, H., Ou, Q., Pai, C., Rodriguez, R., Cheung, J., & Chan, A. C. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001439 · Cited by 49
Metastatic Colonization: Escaping Immune Surveillance
Schaller, J., & Agudo, J. (2020) · Cancers · doi:10.3390/cancers12113385 · Cited by 55
“In the TME, increased transforming growth factor (TGF) β drives T cell exclusion and inhibition of TGFβ potentiates immunotherapy as well as prevents metastasis in colorectal cancer models [105].”
BackgroundA bird’s eye view of fibroblast heterogeneity: A pan‐disease, pan‐cancer perspective
Pradhan, R., Krishnamurty, A. T., Fletcher, A. L., Turley, S. J., & Müller, S. (2021) · Immunological Reviews · doi:10.1111/imr.12990 · Cited by 53
Recent Advances in the Development of TGF-β Signaling Inhibitors for Anticancer Therapy
Lee, H.-J. (2020) · Journal of Cancer Prevention · doi:10.15430/jcp.2020.25.4.213 · Cited by 51
“[47] showed that the inhibition of TGF-β signaling with a TGF-β RI kinase inhibitor triggers the infiltration of CTLs, and renders tumors susceptible to immune checkpoint therapies.”
BackgroundStein, A., & Folprecht, G. (2018) · Oncology Research and Treatment · doi:10.1159/000488918 · Cited by 51
Wang, X., Luo, X., Chen, C., Tang, Y., Li, L., Mo, B., Liang, H., & Yu, S. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0124-z · Cited by 54
Wu, S., Zhang, S.-W., Ma, D., Xiao, Y. Q., Liu, Y., Chen, L., Song, X.-Q., Ma, X.-Y., Xu, Y., Chai, W.-J., et al. (2023) · Med · doi:10.1016/j.medj.2023.04.008 · Cited by 57
Hu, Y., Recouvreux, M. S., Haro, M., Taylan, E., Taylor‐Harding, B., Walts, A. E., Karlan, B. Y., & Oršulić, S. (2024) · npj Precision Oncology · doi:10.1038/s41698-024-00523-y · Cited by 62
Beyond Cancer Cells: How the Tumor Microenvironment Drives Cancer Progression
Sabit, H., Arneth, B. M., Abdel-Ghany, S. E., Madyan, E. F., Ghaleb, A. H., Selvaraj, P., Shin, D. M., Bommireddy, R., & El-Hashash, A. H. K. (2024) · Cells · doi:10.3390/cells13191666 · Cited by 58
“Recent research by Mariathasan et al. [166] and Tauriello et al. [167] suggests that pre-existing immunity and tumor mutation burden are correlated with responses to anti-PD-L1 therapy.”
Wang, C., Hou, L., Wan, J., Yao, H., Yuan, J., Zeng, J., Park, C. W., Kim, S. H., Seo, D. B., Shin, K., et al. (2019) · Journal of Ginseng Research · doi:10.1016/j.jgr.2018.12.010 · Cited by 48
Innate Immune Cells and Their Contribution to T-Cell-Based Immunotherapy
Ginefra, P., Lorusso, G., & Vannini, N. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21124441 · Cited by 49
Host IL11 Signaling Suppresses CD4+ T cell–Mediated Antitumor Responses to Colon Cancer in Mice
Huynh, J., Baloyan, D., Chisanga, D., Shi, W., O'Brien, M., Afshar‐Sterle, S., Alorro, M., Pang, L., Williams, D. S., Parslow, A. C., et al. (2021) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-19-1023 · Cited by 51
Huang, J., Zhang, L., Zhou, W., Wang, J., Zhang, R., Wang, Z., Ran, H., Li, P., & Li, R. (2021) · Biomaterials · doi:10.1016/j.biomaterials.2021.120856 · Cited by 48
Xu, Q., Chen, S., Hu, Y., & Huang, W. (2021) · Cell Death Discovery · doi:10.1038/s41420-021-00663-1 · Cited by 55
“In addition, the activation EMT- and TGF-β-related pathways participated in the formation of peritumoral stroma [24].”
Cohen, R., Colle, R., Pudlarz, T., Heran, M., Duval, A., Svrcek, M., & André, T. (2021) · Cancers · doi:10.3390/cancers13051149 · Cited by 47
Gorchs, L., & Kaipe, H. (2021) · Cancers · doi:10.3390/cancers13122995 · Cited by 64
Hexun, Z., Miyake, T., Maekawa, T., Mori, H., Yasukawa, D., Ohno, M., Nishida, A., Andoh, A., & Tani, M. (2022) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-022-03256-8 · Cited by 53
Hamouda, S. B., & Essafi‐Benkhadir, K. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24065600 · Cited by 53
TGF-β mediated drug resistance in solid cancer
Turati, M., Mousset, A., Issa, N., Turtoï, A., & Ronca, R. (2023) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2023.04.001 · Cited by 50
In situ tumour arrays reveal early environmental control of cancer immunity
Ortiz-Muñoz, G., Brown, M., Carbone, C. B., Pechuan-Jorge, X., Rouilly, V., Lindberg, H., Ritter, A. T., Raghupathi, G., Sun, Q., Nicotra, T., et al. (2023) · Nature · doi:10.1038/s41586-023-06132-2 · Cited by 53
Comprehensive review of the resistance mechanisms of colorectal cancer classified by therapy type
Oh, J. M., Kim, S. W., Tsung, C., Kent, E. W., Jain, A., Ruff, S. M., & Zhang, H. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1571731 · Cited by 56
Loyon, R., Jary, M., Salomé, B., Gomez‐Cadena, A., Galaine, J., Kroemer, M., Romero, P. J., Trabanelli, S., Adotévi, O., Borg, C., et al. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02121 · Cited by 54
Multifaceted transforming growth factor-beta (TGFβ) signalling in glioblastoma
Birch, J. L., Coull, B. J., Spender, L. C., Watt, C., Willison, A., Syed, N., Chalmers, A. J., Hossain-Ibrahim, M. K., & Inman, G. J. (2020) · Cellular Signalling · doi:10.1016/j.cellsig.2020.109638 · Cited by 55
Malenica, I., Donadon, M., & Lleò, A. (2020) · Cancers · doi:10.3390/cancers12082190 · Cited by 50
An emerging role for cellular crosstalk in the cancer stem cell niche
Oshimori, N., Guo, Y., & Taniguchi, S. (2021) · The Journal of Pathology · doi:10.1002/path.5655 · Cited by 51
“Mariathasan et al [51] and Tauriello et al [52] showed that stromal TGF-β signaling could be a determinant factor of T cell exclusion.”
BackgroundSphyris, N., Hodder, M. C., & Sansom, O. J. (2021) · Cancers · doi:10.3390/cancers13051000 · Cited by 52
Pecci, F., Cantini, L., Bittoni, A., Lenci, E., Lupi, A., Crocetti, S., Giglio, E., Giampieri, R., & Berardi, R. (2021) · Current Treatment Options in Oncology · doi:10.1007/s11864-021-00870-z · Cited by 49
The Therapeutic Potential of Tackling Tumor-Induced Dendritic Cell Dysfunction in Colorectal Cancer
Subtil, B., Cambi, A., Tauriello, D. V. F., & de Vries, I. J. M. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.724883 · Cited by 50
Self-citationCancer Cell Phenotype Plasticity as a Driver of Immune Escape in Melanoma
Benboubker, V., Boivin, F., Dalle, S., & Caramel, J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.873116 · Cited by 56
Hamon, P., de Thoré, M. G., Classe, M., Signolle, N., Liu, W., Bawa, O., Meziani, L., Clémenson, C., Milliat, F., Deutsch, É., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003519 · Cited by 52
Altorki, N. K., Borczuk, A., Harrison, S. W., Groner, L. K., Bhinder, B., Mittal, V., Elemento, O., & McGraw, T. E. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110639 · Cited by 52
Bauer, T. M., Santoro, A., Lin, C., Garrido‐Laguna, I., Joerger, M., Greil, R., Spreafico, A., Yau, T. C. C., Goebeler, M.-E., Hütter‐Krönke, M. L., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-007353 · Cited by 53
Newsted, D., Banerjee, S., Watt, K., Nersesian, S., Truesdell, P. F., Blazer, L. L., Cardarelli, L., Adams, J., Sidhu, S. S., & Craig, A. W. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1539613 · Cited by 52
Targeting the Tumor Microenvironment: An Unexplored Strategy for Mutant KRAS Tumors
Carvalho, P. D., Machado, A. L., Martins, F., Seruca, R., & Velho, S. (2019) · Cancers · doi:10.3390/cancers11122010 · Cited by 51
“For instance, TGFβ1 inhibition was shown to promote an anti-tumorigenic immune infiltration of immune-excluded CRC and restored sensitivity to PD-L1/PD-1 blockade [71].”
BackgroundTan, B., Khattak, A., Felip, E., Kelly, K., Rich, P., Wang, D., Helwig, C., Dussault, I., Ojalvo, L. S., & Isambert, N. (2021) · Targeted Oncology · doi:10.1007/s11523-021-00809-2 · Cited by 45
Tajaldini, M., Saeedi, M., Amiriani, T., Amiriani, A., Sedighi, S., Zadeh, F. M., Dehghan, M. H., Jahanshahi, M., Zanjan, M. G., Khalili, P., et al. (2022) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2022.175087 · Cited by 51
de Miguel‐Pérez, D., Russo, A., Gunasekaran, M., Buemi, F., Hester, L., Fan, X., Carter‐Cooper, B., Lapidus, R. G., Peleg, A., Arroyo‐Hernández, M., et al. (2022) · Cancer · doi:10.1002/cncr.34576 · Cited by 51
Chen, L., Jiang, X., Li, Y., Zhang, Q., Li, Q., Zhang, X., Zhang, M., Yu, Q., & Gao, D. (2022) · Clinical Immunology · doi:10.1016/j.clim.2022.108962 · Cited by 50
Chen, B., Mu, C., Zhang, Z., He, X., & Liu, X. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.891268 · Cited by 58
“A colorectal cancer tumor-bearing mouse model confirmed that increased TGF-b levels produced by CAFs in the TME represent a fundamental mechanism of immune evasion that blocks the aggregation of CD4 T helper and cytotoxic CD8 T cells (42).”
BackgroundLiu, L., Wang, Y., Yu, S., Liu, H., Li, Y., Hua, S., & Chen, Y. (2023) · Advanced Science · doi:10.1002/advs.202300708 · Cited by 45
Bispecific antibody targeting TGF-β and PD-L1 for synergistic cancer immunotherapy
Li, T., Wang, X., Niu, M., Wang, M., Zhou, J., Wu, K., & Yi, M. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1196970 · Cited by 66
Immunotherapy resistance in solid tumors: mechanisms and potential solutions
Lefler, D. S., Manobianco, S. A., & Bashir, B. (2024) · Cancer Biology & Therapy · doi:10.1080/15384047.2024.2315655 · Cited by 55
Yahata, T., Ibrahim, A. A., Fujimura, T., Uno, T., Terada, T., Hirano, K.-I., Hosokawa, H., Ohta, A., Miyata, T., & Ando, K. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1365894 · Cited by 48
New therapies and insights into the changing landscape of colorectal cancer
Kopetz, S. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-018-0100-z · Cited by 45
Colorectal cancer: A paradigmatic model for cancer immunology and immunotherapy
Ijsselsteijn, M. E., Pamplona, R. S., Hermitte, F., & de Miranda, N. F. C. C. (2019) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2019.05.003 · Cited by 54
Dynamics of Genomic, Epigenomic, and Transcriptomic Aberrations during Stepwise Hepatocarcinogenesis
Jee, B. A., Choi, J. H., Rhee, H., Yoon, S., Kwon, S. M., Nahm, J. H., Yoo, J. E., Jeon, Y., Choi, G. H., Woo, H. G., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-19-0991 · Cited by 50
Wang, X., Feng, M., Xiao, T., Guo, B., Liu, D., Liu, C., Pei, J., Liu, Q., Xiao, Y. Q., Rosin‐Arbesfeld, R., et al. (2021) · Oncogene · doi:10.1038/s41388-021-01756-y · Cited by 49
Dasgupta, S., Ghosh, T., Dhar, J., Bhuniya, A., Nandi, P. S., Das, A., Saha, A., Das, J., Guha, I., Banerjee, S., et al. (2021) · Cell Death and Differentiation · doi:10.1038/s41418-021-00801-3 · Cited by 49
Ellingsen, E. B., Mangsbo, S. M., Hovig, E. J., & Gaudernack, G. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.682492 · Cited by 48
The Multifaceted Role of TGF-β in Gastrointestinal Tumors
Sabbadini, F., Bertolini, M., Matteis, S. D., Mangiameli, D., Contarelli, S., Pietrobono, S., & Melisi, D. (2021) · Cancers · doi:10.3390/cancers13163960 · Cited by 48
Blenman, K., Marczyk, M., Karn, T., Qing, T., Li, X., Gunasekharan, V. K., Yaghoobi, V., Bai, Y., Ibrahim, E., Park, T., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-3215 · Cited by 49
TGFβ and the Tumor Microenvironment in Colorectal Cancer
Waldner, M. J., & Neurath, M. F. (2023) · Cells · doi:10.3390/cells12081139 · Cited by 57
Löffek, S. (2018) · Journal of Oncology · doi:10.1155/2018/9732939 · Cited by 49
Kwon, M., Kim, C. G., Lee, H., Cho, H., Kim, Y., Lee, E. C., Choi, S. J., Park, J., Seo, I., Bogen, B., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0267 · Cited by 48
“In addition, coinhibition of TGFb and PD-1 promotes robust tumor regression in mouse tumor models (13, 14, 44).”
BackgroundKang, Y., Bang, Y., Kondo, S., Chung, H. C., Muro, K., Dussault, I., Helwig, C., Osada, M., & Doi, T. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3806 · Cited by 49
Metadata
- Authors
- Tauriello, D. V. F., Palomo-Ponce, S., Stork, D., Berenguer-Llergo, A., Badia-Ramentol, J., Iglesias, M., Sevillano, M., Ibiza, S., Cañellas, A., Hernando-Momblona, X., Byrom, D., Matarin, J. A., Calon, A., Rivas, E. I., Nebreda, A. R., Riera, A., Attolini, C. S.-O., & Batlle, E.
- Affiliations
- Institute for Research in Biomedicine (ES)
- Universitat Autònoma de Barcelona (ES)
- Institució Catalana de Recerca i Estudis Avançats (ES)
- Corresponding author
- Batlle, Eduard
- ORCID
- Venue
- Nature
- Published
- 2018-02
- Volume
- 554
- Issue
- 7693
- Pages
- 538-543
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2788975052
- Cited by
- 1,851
- References
- 43
- Citations by year
- 2026: 193 · 2025: 186 · 2024: 159 · 2023: 211 · 2022: 280 · 2021: 305 · 2020: 247 · 2019: 176 · 2018: 94
- FWCI
- 77.71
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RECERCAT (Consorci de Serveis Universitaris de Catalunya) (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona) (submittedVersion, public-domain)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › TGF-β signaling in diseases
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- TGF-beta signaling, colorectal cancer metastasis, immune evasion, T-cell exclusion, tumor microenvironment, immune checkpoint inhibitors, TGF-beta inhibition, liver metastasis, microsatellite stable colorectal cancer, genetically engineered mouse models, organoid transplantation, combination immunotherapy
- MeSH terms
- Alleles, Animals, Cell Differentiation, Colonic Neoplasms, Disease Models, Animal, Drug Synergism, Female, Humans, Immunotherapy, Intestinal Mucosa, Intestines, Liver Neoplasms, Male, Mutation, Neoplasm Metastasis, Stem Cells, T-Lymphocytes, Cytotoxic, Transforming Growth Factor beta, Th1 Cells, Mice, Immune Evasion, Tumor Microenvironment, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.